Annals of Oncology 13:1259-1263, 2002
© 2002 European Society for Medical Oncology
Original Paper |
Neovastat (Æ-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels
1 McGill Center for Translational Research in Cancer, McGill University, Montréal; 2 Les Laboratoires Æterna, Québec; 3 3210308 Canada Inc., Montréal, Canada; 4 Institut Gustave Roussy, Villejuif, France
Received 3 October 2001; revised 19 December 2001; accepted 9 January 2002
Background:
renal cell carcinoma (RCC) is a potential target for anti-angiogenic drugs because of its high vascularization. Neovastat (Æ-941) is an inhibitor of angiogenesis with a mechanism of action that could prove beneficial in the treatment of RCC.
Patients and design
A phase II trial was conducted to identify the long-term safety profile of Neovastat in advanced cancer patients and to obtain preliminary information on its efficacy in solid tumors refractory to standard treatments. Neovastat (60 or 240 ml/day) was administered orally (b.i.d.) to 144 patients with solid tumors refractory to standard therapies or for whom no standard treatments were available.
Results:
A survival analysis was conducted on 22 patients with a primary diagnosis of refractory RCC to determine whether the dose of Neovastat had any effect. A significant relationship between dose and survival was observed; the median survival time was significantly longer (16.3 versus 7.1 months; P = 0.01) in patients treated with Neovastat 240 ml/day (n = 14) compared with patients receiving 60 ml/day (n = 8). No dose-limiting toxicity was reported. The most frequent adverse event was taste alteration (13.6%).
Conclusions:
Neovastat is well tolerated by advanced cancer patients at doses of 60 and 240 ml/day. The higher dose of Neovastat administered in this trial is associated with a survival benefit in RCC, which is not explained by differences in major prognostic factors.
Key words: Æ-941, angiogenesis, anti-angiogenic agent, clinical trial, Neovastat, renal cell carcinoma
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Roy, J. Yang, and M. A. Moses Matrix Metalloproteinases As Novel Biomarkers and Potential Therapeutic Targets in Human Cancer J. Clin. Oncol., November 1, 2009; 27(31): 5287 - 5297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Munshi, L. H. Ni, and M. S. Tiwana Complementary and Alternative Medicine in Present Day Oncology Care: Promises and Pitfalls Jpn. J. Clin. Oncol., August 5, 2008; (2008) hyn066v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nikkola, P. Vihinen, M.-S. Vuoristo, P. Kellokumpu-Lehtinen, V.-M. Kahari, and S. Pyrhonen High Serum Levels of Matrix Metalloproteinase-9 and Matrix Metalloproteinase-1 Are Associated with Rapid Progression in Patients with Metastatic Melanoma Clin. Cancer Res., July 15, 2005; 11(14): 5158 - 5166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I. Rini and E. J. Small Biology and Clinical Development of Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma J. Clin. Oncol., February 10, 2005; 23(5): 1028 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Gordon Novel Antiangiogenic Therapies for Renal Cell Cancer Clin. Cancer Res., September 15, 2004; 10(18): 6377S - 6381S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Kerr A word in your ear: the 2004 Annals of Oncology prizes Ann. Onc., September 1, 2004; 15(9): 1303 - 1304. [Full Text] [PDF]
|
|
|
|
|
|
K. Schmidt and E. Ernst Assessing websites on complementary and alternative medicine for cancer Ann. Onc., May 1, 2004; 15(5): 733 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vickers Alternative Cancer Cures: "Unproven" or "Disproven"? CA Cancer J Clin, March 1, 2004; 54(2): 110 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Cassileth and G. Deng Complementary and Alternative Therapies for Cancer Oncologist, February 1, 2004; 9(1): 80 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Wahl, T. L. Moser, and S. V. Pizzo Angiostatin and Anti-angiogenic Therapy in Human Disease Recent Prog. Horm. Res., January 1, 2004; 59(1): 73 - 104. [Abstract] [Full Text]
|
|
|
|
 |
|
 V. Chhokar and A. L. Tucker Angiogenesis: Basic Mechanisms and Clinical Applications Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 253 - 280. [Abstract] [PDF]
|
|
|
|
 |
|
 W. A. Weiger, M. Smith, H. Boon, M. A. Richardson, T. J. Kaptchuk, and D. M. Eisenberg Advising Patients Who Seek Complementary and Alternative Medical Therapies for Cancer Ann Intern Med, December 3, 2002; 137(11): 889 - 903. [Abstract] [Full Text] [PDF]
|
|